Although MOG-IgG has become a new diagnostic marker for neuromyelitis optica (NMO) but not MS (112), we do not know if MOG-IgE is derived from MOG-IgG via class-switching in this pre-clinical study and if MOG-IgE may potentially contribute to NMO or MS. This evidence concerns the gene IGHE and myeloid sarcoma.